Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT03252938 |
| Title | Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors (INSIGHT) |
| Acronym | INSIGHT |
| Recruitment | Active, not recruiting |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | DEU |